Birinapant clinical study initiated by IGM Biosciences
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444 (NCT04553692). The combination of IGM-8444 and birinapant has previously shown to enhance anti-tumor activity preclinically. The purpose of this first clinical trial with the combination will be to explore safety and tolerability. In January 2021, Medivir entered into an exclusive licensing agreement through which IGM Biosciences received global,